Efficacy and safety of rotigotine transdermal patch for Parkinson’s disease：a systematic review

Abstract:

Objective：To evaluate the efficacy，tolerability，and safety of rotigotine transdermal patch in Parkinson’s disease. Methods：The PubMed，Cochrane Library databases，EMBASE，and Web of Knowledge were searched for the randomized clinical trial（RCT） of rotigotine transdermal patch in Parkinson’s disease. RevMan 5.1 software was used to analyze the data. Results：（1） Seven large-scale RCTs，involving 1 969 patients were included in this meta-analysis. （2）The results showed：①Efficacy：compared with placebo，the use of rotigotine resulted in greater improvement in UPDRS Ⅱ score（WMD=-1.69，95%CI=-2.18 to -1.19，P=0.000） and Ⅲ score（WMD=-3.86，95%CI=-4.86 to -2.86，P=0.000）. ②Tolerability：no difference was found in overall withdrawals（RR=0.88，95%CI=0.64 to 1.21，P=0.44），but rotigotine was associated with a significantly higher rate of withdrawals due to adverse events（RR=1.82，95%CI=1.29 to 2.59，P=0.000）. ③Safety：rotigotine was associated with a significantly higher rate of application site reactions（RR=2.77，95%CI=2.23 to 3.43，P=0.000），vomiting（RR=6.15，95%CI=2.88 to 13.13，P=0.000），and dyskinesia（RR=2.52，95%CI=1.47 to 4.32，P=0.000） compared with placebo. Conclusion：The use of rotigotine can reduce the symptoms of PD. However，rotigotine is also associated with a higher incidence of adverse events，especially application site reactions.